The life sciences industry has long been driven by innovation. From drug discovery and clinical development to advanced manufacturing and personalized medicine, life sciences companies continuously push the boundaries of science and technology. Today, artificial intelligence (AI) is accelerating that innovation cycle, creating new opportunities, and new considerations for companies seeking to benefit from the federal Research and Development (R&D) Tax Credit.
As AI becomes increasingly embedded within life sciences organizations, taxpayers must understand how AI-driven activities fit within the statutory requirements of Internal Revenue Code (IRC) Section 41 and ensure they maintain appropriate documentation to support credit eligibility.
Artificial intelligence is rapidly transforming the life sciences sector. Organizations are leveraging machine learning algorithms, predictive analytics, large language models, and advanced computational tools to support activities such as:
These technologies have the potential to reduce development timelines, improve decision-making, and increase the efficiency of research programs. As a result, many life sciences companies are increasing investments in AI-enabled research platforms and data-driven innovation strategies.
However, from an R&D tax credit perspective, the use of AI alone does not automatically qualify an activity for the credit.
The federal R&D tax credit is governed by IRC Section 41. To qualify, research activities generally must:
The introduction of AI into the research process does not change these requirements. Instead, the qualification analysis must focus on whether the underlying activity advances scientific or technological knowledge and whether technical uncertainty exists regarding the capability, methodology, or appropriate design.
For life sciences companies, this distinction is especially important. Using AI to automate routine analyses or evaluate existing data may not, by itself, constitute qualified research. Conversely, developing novel algorithms, creating new computational models, improving predictive capabilities, or using AI to solve previously unresolved scientific challenges strengthen the case for credit eligibility when the statutory requirements are satisfied.
The focus should remain on the scientific or technological uncertainty being addressed, not simply the technology being utilized.
One of the most significant opportunities AI presents is the potential to improve R&D credit documentation.
The IRS continues to emphasize the importance of substantiating qualified research activities and related expenditures. Life sciences organizations often generate large volumes of technical data, laboratory records, experimental results, design documentation and project management information.
AI-enabled systems can help organize and analyze information generated throughout the research lifecycle by:
These capabilities may help strengthen the connection between research activities and the statutory requirements necessary to claim the credit. However, taxpayers should ensure that AI-generated documentation accurately reflects the underlying research and does not replace the need for technical personnel to explain the uncertainty, experimentation and technological advancement achieved throughout the project.
As life sciences companies continue to invest in AI, understanding how these activities align with IRS requirements is critical to maximizing available incentives while maintaining audit-ready documentation. Withum offers a no- obligation complimentary R&D tax credit assessment, beginning with a brief 30-minute discussion. This conversation is designed to quickly determine whether an R&D tax credit opportunity exists and how Withum can assist in calculating, documenting, and supporting your credit through our innovative, technology- driven R&D tax credit studies.
For more information on this topic, please contact a member of our team.
New York is expanding access to agricultural tax incentives and related programs for licensed cannabis cultivators through recent legislative changes. As a result, qualifying growers may now be able to take advantage of benefits ranging from property tax relief and refundable investment tax credits to workforce, redevelopment and energy-efficiency incentives. Understanding how these programs work…
For many startup companies, innovation comes long before profitability. While early-stage businesses often invest heavily in software development, product design, engineering or process improvement, they may have little or no federal income tax liability against which to utilize valuable tax credits. Recognizing this challenge, Congress created a special provision that allows startup companies to monetize…
For emerging life sciences companies, the Qualified Small Business (QSB) election under IRC §41(h) offers a critical opportunity to monetize research and development (R&D) tax credits by applying them against payroll tax liabilities. However, the strategic decision of when to first make the QSB election is often overlooked. Thoughtful timing, particularly in an industry characterized…
